Yes, and with the solid growth in the quarter, we're now approaching 6.8 billion in rolling 12 months net revenues and a rolling 12 months adjusted EBIT margin of 4.7%. We didn't have any items affecting comparability in the quarter. Last year, we had non-recurring items of 24 million, and those costs were related to the IPO in December. Let's focus on the growth for the quarter. As mentioned, we had growth of 15.2%. We had more or less equal growth in Rx as well as in OTC and traded goods. Hence, you can see that the product mix in the quarter is in line with what it was a year ago.
Go. The growth was primarily driven by a solid and stable underlying market demand, and also affected by the fact that Easter took place after the end of the period.
To the right you can see our gross margin development.
We had a fairly stable gross margin, slightly increased, and that increase is due to improved purchasing terms.
We were able to increase our profitability in Q1 compared to Q1 24.
Ebit increased from 62 million to 92 million, and the margin uplift is the result of the increased profitability, the increased gross margin, and also continued tight cost control, cost management, and an increased capacity utilization.
In line with what we've said before, in line with earlier communication, we expect our costs related to Varberg to gradually increase as we start production there this summer and ramp up the organization on site. You see, our costs and depreciation as a percentage of net revenue have been going down year over year. As you can see, personnel costs in relation to sales decreased from 8.6% to 7.5%.
And that decrease was the result of increased efficiency. And also, today we are using external staffing to a larger extent than a year ago, meaning that we're shifting costs from personnel costs to other operating costs. We increased our operating cash flow from 78 million in Q1 2024 to 123 million in Q1 2025. The operating cash flow financed the investments in the period of 117 million, and that investment was mainly related to our new fulfillment center in Varberg, and the increased operational cash flow was due to the increased profitability.
To the right, you see a breakdown of net working capital inventory. Inventory turnover was 8.7 times and slightly increased from a year ago.
The net working capital will fluctuate over time and there will be variations from quarter to quarter. Finally, let's have a look at the balance sheet and some balance sheet ratios.
Um, to the left you can see our return on capital employed.
Return on capital employed was close to 34% and increased from a year ago due to the increased profitability.
We maintain a solid balance sheet and a low net debt despite our investments in Varberg.
As of the end of Q1, we had a net debt to EBITDA ratio of 0.2.